The 2017 Summer Scholars Working at the SENS Research Foundation
Each year, the SENS Research Foundation accepts a group of young life science academics and puts them to work on projects in aging research, both at the foundation and in allied laboratories, creating ties between research groups that can help to advance the state of the art. This year's batch has worked on a diverse set of projects that spread out beyond core SENS initiatives such as allotopic expression of mitochondrial genes. Reading through their projects is a reminder that a great deal can be accomplished these days given a small team, a little funding, and an equipped laboratory. Progress in medical research is no lo...
Source: Fight Aging! - August 26, 2017 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
We Need To Raise The Bar To Improve Cancer Treatments. What ’s The Best Way To Do It?
Over the past 20 years, we have witnessed an unprecedented development of new life-science technologies. Although clinical outcomes have also improved, the benefits often remain out of reach for many patients. Translating scientific and technological gains into clinically meaningful outcomes that are accessible and affordable to all who need them is one of the great challenges of our time.
Several prominent voices have called on the field to “raise the bar” and aim higher in research efforts, to measurably and meaningfully lengthen and improve patients’ lives. The American Society of Clinical Oncology (ASCO), for exa...
Source: Health Affairs Blog - July 26, 2017 Category: Health Management Authors: Jacqueline Zummo Tags: Drugs and Medical Innovation clinical trials Source Type: blogs
How Soon To Start Treatment?
I never realized how important starting cancer treatment quickly was. I remember my surgeon telling me at one point I had plenty of time to wait before making decisions for my treatment. I guess that wasn ' t true.There is a new study (because we always need new studies) to focus on the TTI (Time to Treatment Initiation) from date of diagnosis. As that increases, the cancer death rates increase as well. How nice. So don ' t wait, start NOW!Research by the Cleveland Clinic showed a increase from 21 to 29 days showed increased mortality." Longer delays between diagnosis and initial treatment were associated with worsened ove...
Source: Caroline's Breast Cancer Blog - July 24, 2017 Category: Cancer & Oncology Tags: breast cancer treatment cancer research Source Type: blogs
Adenocarcinoma in Situ : RadioPath Correlation
In situ pulmonary adenocarcinoma (AIS), previously called "Bronchioloalveolar carcinoma" (BAC), is a term describing certain variants of lung cancer arising in the distal bronchioles or alveoli that initially exhibit a specific non-invasive growth pattern. BAC is a type of non-small-cell lung cancer (NSCLC). Here is video discussing the Radio-path correlationFamous Radiology Blog http://www.sumerdoc.blogspot.com
TeleRad Providers at www.teleradproviders.com Mail us at sales@teleradproviders.com (Source: Sumer's Radiology Site)
Source: Sumer's Radiology Site - June 1, 2017 Category: Radiology Authors: Sumer Sethi Source Type: blogs
Top Companies in Genomics
From portable genome sequencers until genetic tests revealing distant relations with Thomas Jefferson, genomics represents a fascinatingly innovative area of healthcare. As the price of genome sequencing has been in free fall for years, the start-up scene is bursting from transformative power. Let’s look at some of the most amazing ventures in genomics!
The amazing journey of genome sequencing
Genome sequencing has been on an amazing scientific as well as economic journey for the last three decades. The Human Genome Project began in 1990 with the aim of mapping the whole structure of the human genome and sequencing it. ...
Source: The Medical Futurist - May 30, 2017 Category: Information Technology Authors: nora Tags: Genomics Personalized Medicine AI artificial intelligence bioinformatics cancer DNA dna testing DTC gc3 genetic disorders genetics genome sequencing personal genomics precision medicine Source Type: blogs
The Humanity In End-Of-Life Care
Health care is personal, especially when it comes to caring for someone as they approach death. However, half of Americans feel they have too little control over end-of-life medical decisions.
As the industry moves toward a more holistic approach to care delivery, health care organizations are beginning to rethink how they treat patients and starting to embed end-of-life care plans into the overall approach earlier on, sometimes before people even become ill. In a recent report on end-of-life care by the Aspen Health Strategy Group, several principles are discussed that take a broader view around caring for seriously ill p...
Source: Health Affairs Blog - May 19, 2017 Category: Health Management Authors: Susan DeVore Tags: Costs and Spending End of Life & Serious Illness Long-term Services and Supports Payment Policy Quality advance care planning Palliative Care Source Type: blogs
Overcoming Challenges Of Outcomes-Based Contracting For Pharmaceuticals: Early Lessons From The Genentech – Priority Health Pilot
Conclusion
Outcomes-based agreements are a natural extension of a health care delivery-and-reimbursement environment that is moving toward value. With provider organizations taking increasing accountability for both costs and outcomes, it is becoming incumbent upon manufacturers to demonstrate the economic, clinical, and quality-of-life benefits of their medicines. The pilot described here was successful in that Genentech and Priority Health both learned how to overcome clinical, operational, and contractual challenges and demonstrated that this type of agreement is feasible. Genentech and Priority Health believe pilots li...
Source: Health Affairs Blog - April 3, 2017 Category: Health Management Authors: John Fox and Marc Watrous Tags: Costs and Spending Drugs and Medical Innovation Payment Policy Outcomes-based agreements Source Type: blogs
Patients with Lung Cancer (NSCLC) Refusing Treatment; Pessimism about Cancer
Some patients with cancer will occasionally refuse therapy, particularly when their situation is considered hopeless. I thought that this was largely an attitude of the past until I came across a recent article about patients saying"no" to therapy (see:Lung Cancer Survival Shortens as Patients No' to Tx). Below is an excerpt from it:The number of patients with advanced lung cancer who decide not to undergo treatment is increasing despite better systemic treatments that are more tolerable and that significantly improve overall survival....Analysis of data from the Nati...
Source: Lab Soft News - February 9, 2017 Category: Laboratory Medicine Authors: Bruce Friedman Tags: Cost of Healthcare Healthcare Delivery Medical Consumerism Medical Research Quality of Care Source Type: blogs
ASCO Supports Concurrent Palliative Care for People with Advanced Cancer
by Christian SinclairTheAmerican Society of Clinical Oncology recentlypublished the strongest call for concurrent palliative care in oncology. Released online on Halloween 2016, and published in the Journal of Clinical Oncology just last month, this Clinical Practice Guideline (CPG) should be in the pocket of every palliative care team as they meet with their oncology colleagues to collaborate on better care for patients.The guideline holds more weight and expands the scope compared to the 2012 Provisional Clinical Opinion which emerged after the Temel article. In 2010,NEJM published a randomized control trial (RCT) of pal...
Source: Pallimed: A Hospice and Palliative Medicine Blog - February 7, 2017 Category: Palliative Care Tags: ASCO guidelines non-pain symptoms oncology sinclair Source Type: blogs
What Does the Scan Tell Us? An analysis of oncology outpatient visits
Discussions: Insights Into Why Patients Misunderstand Their Prognosis, " which was published online early in the Journal of Oncology Practice. (OPEN ACCESS PDF!)The researchers analyzed recordings of oncologists and patients with stage IIIA, IIIB, or IV non-small cell lung cancer in the outpatient setting. These recordings were from another large study and are over a decade old now. But as the authors pointed out, there is not strong evidence that outpatient communication strategies have changed wholesale in oncology, (although treatment options have changed drastically with the introduction of checkpoint inhibitors, but t...
Source: Pallimed: A Hospice and Palliative Medicine Blog - January 30, 2017 Category: Palliative Care Tags: clinic communication journal article oncology outpatient prognosis sinclair Source Type: blogs
Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement
Advances in foundational science, technology, and clinical knowledge are driving a revolution in patient care. Minimally invasive surgery has reduced rates of post-surgical complications, reduced hospitalization, and dramatically accelerated recovery; direct-acting antivirals have brought a cure for hepatitis C; and novel immunotherapies have brought the promise of increased survival to late-stage cancer patients. The list goes on.
At the same time, spending on these innovative drugs and devices has increased dramatically. Between 1980 and 2010, overall personal health care expenditures in the US grew nearly four-fold, dri...
Source: Health Affairs Blog - September 15, 2016 Category: Health Management Authors: Dana Goldman, Samuel Nussbaum and Mark Linthicum Tags: Drugs and Medical Innovation Featured Comparative Effectiveness health technology assessment National Health Service National Institute for Health and Care Excellence PCORI Source Type: blogs
Over the Edge Spotlight: Patty Watkins
This weekend, on September 10, Team LIVESTRONG is partnering withOver the Edge for an all new event experience! We will be taking fundraising to new heights in Atlanta, Georgia as we rappel down the side of Buckhead Tower to raise funds for LIVESTRONG‘s free programs and services. Here, we have a short Q&A with one of the participants, Patty Watkins!LS: How have you been affected by cancer?
Patty: I have been affected by cancer in many ways. I have Stage 4 Non-Small Cell Lung Cancer, metastatic; now, it’s in my brain. I have always been healthy, very active, ate well, and exercised daily by stren...
Source: LIVESTRONG Blog - September 5, 2016 Category: Cancer & Oncology Authors: LIVESTRONG Staff Source Type: blogs
Adjuvant chemotherapy improves overall survival in patients with stage IB non-small cell lung cancer
The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3 – 7 cm.
Related Posts:EORTC-ETOP study opens on pembrolizumab designed for…Immunotherapy with live bacterium improves response rate in…Chemoradiotherapy after surgery for gastric malignancy showsNew nanopharmaceutical may help overcome resistance to…Drug shows surprising efficacy as therapy for chronic…The post Adjuvant chemotherapy improves overall survival in patients with stage IB non-small cell lung cancer a...
Source: My Irritable Bowel Syndrome Story - June 13, 2016 Category: Gastroenterology Authors: Ken Tags: IBS News Source Type: blogs
DOJ Announces Genentech and OSI Pharmaceuticals, LLC Settlement
The Department of Justice (DOJ) has announced that pharmaceutical companies Genentech and OSI Pharmaceuticals, LLC, will pay $67 million to resolve allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat lung cancer.
This settlement resolves allegations "that between January 2006 and December 2011, Genentech OSI Pharmaceuticals made misleading representations to physicians and other health care providers about the effectiveness of Tarceva to treat certain patients with non-small cell lung cancer, when there was little evidence to show that Tarceva was effective to treat those...
Source: Policy and Medicine - June 6, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases.
The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan" dise...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
